Steven Rosenberg, Friedrich Graf Finckenstein: FDA recognition of TIL therapy is the result of 40 years of research

The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)
Cancer centers fund small grants to boost morale amid low paylines

As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.

January 30, 2026

Vol.52 No.04

By Paul Goldberg and Claire Marie Porter

Capitol Hill

FY26 funding package blocked in Senate after ICE shooting of Alex Pretti
New package—likely excluding DHS—may go back to House early next week

An argument can be made that anyone who has attempted to follow the path of spending bills on Capitol Hill over the past ten days should be evaluated for whiplash.

FDA delays drug reviews in new voucher program amid safety, efficacy concerns

The reviews of two drugs granted priority review via FDA’s new priority voucher program, Commissioner’s National Priority Voucher (CNPV) Pilot Program, have been delayed.

January 30, 2026

Vol.52 No.04

By Claire Marie Porter

Clinical Roundup

UTSW researchers boost the power of CAR T cells to fight cancer

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes engineered cancer-fighting immune cells behave more like stem cells, improving their therapeutic effectiveness. The study suggests new strategies for improving the efficacy of these immune cells, known as chimeric antigen receptor T cells.

January 30, 2026

Vol.52 No.04

Drugs & Targets

FDA approves Darzalex Faspro as quad regimen for all newly diagnosed MM

FDA has approved Darzalez Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. D-VRd is the only anti-CD38 antibody-based regimen with approved indications across newly diagnosed patients, regardless of transplant eligibility.

January 30, 2026

Vol.52 No.04

Clinical

Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer

A story is told that after first obtaining approval for marketing Premarin in 1942, Wyeth Laboratories didn’t lock up the secret recipe for making the hormonal drug in a company safe, to be guarded by patent lawyers.

January 23, 2026

Vol.52 No.03

By Claire Marie Porter

Steven Rosenberg, Friedrich Graf Finckenstein: FDA recognition of TIL therapy is the result of 40 years of research

YOU MAY BE INTERESTED IN

The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)
Cancer centers fund small grants to boost morale amid low paylines

FY26 funding package blocked in Senate after ICE shooting of Alex Pretti
New package—likely excluding DHS—may go back to House early next week

FDA delays drug reviews in new voucher program amid safety, efficacy concerns

UTSW researchers boost the power of CAR T cells to fight cancer

FDA approves Darzalex Faspro as quad regimen for all newly diagnosed MM

Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer

Renew today!

Subscriber content

Never miss an issue!

Login

Steven Rosenberg, Friedrich Graf Finckenstein: FDA recognition of TIL therapy is the result of 40 years of research

YOU MAY BE INTERESTED IN

The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)Cancer centers fund small grants to boost morale amid low paylines

FY26 funding package blocked in Senate after ICE shooting of Alex PrettiNew package—likely excluding DHS—may go back to House early next week

FDA delays drug reviews in new voucher program amid safety, efficacy concerns

UTSW researchers boost the power of CAR T cells to fight cancer

FDA approves Darzalex Faspro as quad regimen for all newly diagnosed MM

Premarin’s 84-year hold on the market ends as FDA approves a generic versionTrade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer

Never miss an issue!

Login

The Directors: Gary Schwartz and Ramon Parsons on the best of times (for science), the worst of times (for funding)
Cancer centers fund small grants to boost morale amid low paylines

FY26 funding package blocked in Senate after ICE shooting of Alex Pretti
New package—likely excluding DHS—may go back to House early next week

Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer